Quantcast

Latest Infliximab Stories

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-14 12:31:58

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-14 08:28:16

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_5eu_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-13 00:21:38

- This Is First Study to Demonstrate Clinical Benefit of Oral alpha 4 Integrin Antagonist in Patient with Inflammatory Bowel Disease - TOKYO, May 13, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in patients with ulcerative colitis were presented in the Joint Presidential Plenary Session at Digestive Disease Week (DDW)...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-04-30 10:21:24

May provide therapeutic target for treating inflammatory bowel disease and preventing colitis-associated colorectal cancer, according to new research published in the American Journal of Pathology The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease (IBD) as well as preventing colitis-associated colorectal cancer, say scientists. Targeting CD146 with anti-CD146 antibody AA98, especially in...

2014-03-27 08:33:57

DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/x6dsmh/therapeutic_class) has announced the addition of the "Therapeutic Class Overview : Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With three products and eight players already in market - Japan biosimilar market will enter new phase...

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-03-20 08:29:06

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. "Since treatment options are limited, we welcome research that evaluates new options for patients suffering...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related